Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH2] in postmenopausal women with osteoporosis

Bone

Volumn 53, Issue 1, 2013, Pages 160-166

  Henriksen, K ^a   Andersen, J R ^a   Riis, B J ^a   Mehta, N ^b   Tavakkol, R ^b   Alexandersen, P ^c   Byrjalsen, I ^a   Valter, I ^d   Nedergaard, B S ^c   Teglbjaerg C S ^c   Stern, W ^b   Sturmer, A ^b   Mitta, S ^b   Nino, A J ^e   Fitzpatrick, L A ^e   Christiansen, C ^a,c   Karsdal, M A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Unigene Laboratories Incorporated   (United States)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^d Center for Clinical and Basic Research   (Estonia)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Anabolic; Osteoporosis; RhPTH(1 31)NH2; Teriparatide

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PLACEBO; RECOMBINANT HUMAN PARATHYROID HORMONE[1-31] AMIDE; RECOMBINANT PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FAINTNESS; FEMALE; HUMAN; HYPERCALCEMIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OSSIFICATION; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRESYNCOPE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS;

EID: 84871916432     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.11.045     Document Type: Article

References (23)

1. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
2. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018-2026.
3. Verhaar H.J., Lems W.F. PTH analogues and osteoporotic fractures. Expert Opin Biol Ther 2010, 10:1387-1394.
4. Dobnig H. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opin Pharmacother 2004, 5:1153-1162.
5. Jouishomme H., Whitfield J.F., Gagnon L., Maclean S., Isaacs R., Chakravarthy B., et al. Further definition of the protein kinase C activation domain of the parathyroid hormone. J Bone Miner Res 1994, 9:943-949.
6. Rixon R.H., Whitfield J.F., Gagnon L., Isaacs R.J., Maclean S., Chakravarthy B., et al. Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase. J Bone Miner Res 1994, 9:1179-1189.
7. Whitfield J.F., Morley P., Willick G.E., Ross V., Barbier J.R., Isaacs R.J., et al. Stimulation of the growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment, hPTH-(1-31)NH2 (Ostabolin). Calcif Tissue Int 1996, 58:81-87.
8. Mohan S., Kutilek S., Zhang C., Shen H.G., Kodama Y., Srivastava A.K., et al. Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone 2000, 27:471-478.
9. Fraher L.J., Avram R., Watson P.H., Hendy G.N., Henderson J.E., Chong K.L., et al. Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans. J Clin Endocrinol Metab 1999, 84:2739-2743.
10. Karsdal M.A., Henriksen K., Bay-Jensen A.C., Molloy B., Arnold M., John M.R., et al. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol 2011, 51:460-471.
11. Iyer H., Khedkar A., Verma M. Oral insulin - a review of current status. Diabetes Obes Metab 2010, 12:179-185.
12. Steinert R.E., Poller B., Castelli M.C., Friedman K., Huber A.R., Drewe J., et al. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther 2009, 86:644-650.
13. Mehta N., Erickson K., Stern W., Sturmer A., Petti D., Mitta S., et al. Nighttime dosing with an oral calcitonin tablet significantly reduces plasma CTX-1. J Bone Miner Res 2009, 24(Suppl. 1):S370.
14. Mehta N., Erickson K., Stern W., Consalvo A., Shields P., Sturmer A., et al. Pharmacokinetic clinical studies of an orally delivered recombinant PTH analog. J Bone Miner Res 2009, 24(Suppl. 1):1249.
15. Hodsman A.B., Hanley D.A., Ettinger M.P., Bolognese M.A., Fox J., Metcalfe A.J., et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:5212-5220.
16. Hammerle S.P., Mindeholm L., Launonen A., Kiese B., Loeffler R., Harfst E., et al. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone 2012, 50:965-973.
17. Binkley N., Bolognese M., Sidorowicz-Bialynicka A., Vally T., Trout R., Miller C., et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the ORACAL trial. J Bone Miner Res 2012, 27(8):1821-1829.
18. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
19. Marcus R., Wang O., Satterwhite J., Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:18-23.
20. Heaney R.P., Watson P. Variability in the measured response of bone to teriparatide. Osteoporos Int 2011, 22:1703-1708.
21. Sellmeyer D.E., Black D.M., Palermo L., Greenspan S., Ensrud K., Bilezikian J., et al. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int 2007, 18:973-979.
22. Watts N.B., Miller P.D., Kohlmeier L.A., Sebba A., Chen P., Wong M., et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. J Bone Miner Res 2009, 24:1125-1131.
23. Whitfield J.F., Isaacs R.J., Chakravarthy B., Maclean S., Morley P., Willick G., et al. Stimulation of protein kinase C activity in cells expressing human parathyroid hormone receptors by C- and N-terminally truncated fragments of parathyroid hormone 1-34. J Bone Miner Res 2001, 16:441-447.